Patricia Pérez-Galán

Research group

Microenvironment in lymphoma pathogenesis and therapy Group leader (R4)

pperez@recerca.clinic.cat 0000-0003-3895-5024

Follow it on:

The Researchgate of Patricia . This link opens in a new tab.

Featured publications

Patient-derived follicular lymphoma spheroids recapitulate lymph node signaling and immune profile uncovering galectin-9 as a novel immunotherapeutic target

Authors:
Dobano-Lopez, Celia; Valero, Juan Garcia; Araujo-Ayala, Ferran; Nadeu, Ferran; Gava, Fabien;

(...)

Lopez-Guillermo, Armando; Magnano, Laura; Colomer, Dolors; Bezombes, Christine; Perez-Galan, Patricia.

Reference: Blood Cancer Journal 2024.
Patient-derived lymphoma spheroids integrating immune tumor microenvironment as preclinical follicular lymphoma models for personalized medicine

Authors:
Faria, Carla; Gava, Fabien; Gravelle, Pauline; Valero, Juan Garcia; Dobano-Lopez, Celia;

(...)

Fournie, Jean-Jacques; Ysebaert, Loic; Laurent, Camille; Perez-Galan, Patricia; Bezombes, Christine.

Reference: Journal For Immunotherapy Of Cancer 2023.
A novel patient-derived 3D model recapitulates mantle cell lymphoma lymph node signaling, immune profile and in vivo ibrutinib responses

Authors:
Araujo-Ayala, Ferran; Dobano-Lopez, Celia; Valero, Juan Garcia; Nadeu, Ferran; Gava, Fabien;

(...)

Lopez-Guillermo, Armando; Gine, Eva; Colomer, Dolors; Bezombes, Christine; Perez-Galan, Patricia.

Reference: Leukemia 2023.
The receptor of the colony-stimulating factor-1 (CSF-1R) is a novel prognostic factor and therapeutic target in follicular lymphoma

Authors:
Valero, Juan Garcia; Matas-Cespedes, Alba; Arenas, Fabian; Rodriguez, Vanina; Carreras, Joaquim;

(...)

Cid, Maria C; Campo, Elias; Lopez-Guillermo, Armando; Colomer, Dolors; Perez-Galan, Patricia.

Reference: Leukemia 2021.
3D Model Characterization by 2D and 3D Imaging in t(14;18)-Positive B-NHL: Perspectives for In Vitro Drug Screens in Follicular Lymphoma

Authors:
Gava, F; Faria, C; Gravelle, P; Bordenave, J; Fournié, JJ;

(...)

Gomes, A; Lagarde, JM; Rossi, C; Pieruccioni, L; Rouquette, J.

Reference: Cancers 2021.
PI3Kδ inhibition reshapes follicular lymphoma-immune microenvironment cross talk and unleashes the activity of venetoclax

Authors:
Serrat, Neus; Guerrero-Hernandez, Martina; Matas-Cespedes, Alba; Yahiaoui, Anella; Valero, Juan G;

(...)

Hodson, Daniel J; Lopez-Guillermo, Armando; Colomer, Dolors; Tannheimer, Stacey; Perez-Galan, Patricia.

Reference: Blood Advances 2020.
Daratumumab displays in vitro and in vivo anti-tumor activity in models of B-cell non-Hodgkin lymphoma and improves responses to standard chemo-immunotherapy regimens

Authors:
Vidal-Crespo, Anna; Matas-Cespedes, Alba; Rodriguez, Vanina; Rossi, Cedric; Valero, Juan G;

(...)

Bezombes, Christine; van Bueren, Jeroen Lammerts; Chiu, Christopher; Doshi, Parul; Perez-Galan, Patricia.

Reference: Haematologica 2020.
The Bruton tyrosine kinase inhibitor CC-292 shows activity in mantle cell lymphoma and synergizes with lenalidomide and NIK inhibitors depending on nuclear factor-κB mutational status

Authors:
Vidal-Crespo, Anna; Rodriguez, Vanina; Matas-Cespedes, Alba; Lee, Eriong; Rivas-Delgado, Alfredo;

(...)

Lopez-Guillermo, Armando; Lopez-Guerra, Monica; Roue, GaeL; Colomer, Dolors; Perez-Galan, Patricia.

Reference: Haematologica 2017.
The Human CD38 Monoclonal Antibody Daratumumab Shows Antitumor Activity and Hampers Leukemia-Microenvironment Interactions in Chronic Lymphocytic Leukemia

Authors:
Matas-Cespedes, Alba; Vidal-Crespo, Anna; Rodriguez, Vanina; Villamor, Neus; Delgado, Julio;

(...)

Wiestner, Adrian; Parren, Paul W H I; Doshi, Parul; van Bueren, Jeroen Lammerts; Perez-Galan, Patricia.

Reference: Clinical Cancer Research 2017.
Disruption of Follicular Dendritic Cells-Follicular Lymphoma Cross-talk by the Pan-PI3K Inhibitor BKM120 (Buparlisib)

Authors:
Matas-Cespedes, Alba; Rodriguez, Vanina; Kalko, Susana G; Vidal-Crespo, Anna; Rosich, Laia;

(...)

Campo, Elias; Roue, Gael; Lopez-Guillermo, Armando; Colomer, Dolors; Perez-Galan, Patricia.

Reference: Clinical Cancer Research 2014.

Featured Projects

Red transpirenaica de terapias avanzadas en linfoma no Hodgkin (THERAVLINFO)

Principal investigator: Patricia Pérez Galán

Funder: POCTEFA-INTERREG, European Union

Code: EFA 123/1

Duration: 01/01/2024 - 31/12/2025
Vascularized lymphoma on-chip: a multifaceted tool for translational research (MyLymphoTool)

Principal investigator: Patricia Pérez Galán

Funder: Fundació La Caixa

Code: HR22-00395

Duration: 01/12/2022 - 30/11/2025
Dual CD19-CAR-T approaches to counteract antigen escape and tumor microenvironment immune suppression in FL

Principal investigator: Patricia Pérez Galán

Funder: Follicular Lymphoma Foundation

Code: INT_Milken_FLF_22

Duration: 01/12/2022 - 30/11/2024
Vascular and extracellular matrix remodeling in follicular lymphoma: implications in the transformation to an aggressive lymphoma and immunotherapy efficacy (VASCEM_LYMPHO)

Principal investigator: Patricia Pérez Galán

Funder: Agencia Estatal de Investigacion (AEI)

Code: PID2021-124894OB-I00

Duration: 01/09/2022 - 31/08/2025
Patient Derived Organoids 2.0: Annotated immunocompetent organoid platforms in solid and hematological tumors as living labs for the optimization and design of current and novel immunotherapies and cellular therapies. CIBERONC (Strategic Action-Towards Ca

Principal investigator: Patricia Pérez Galán

Duration: 01/07/2021 - 01/07/2023

Patricia Pérez-Galán

Research group

Featured publications

Featured Projects

Red transpirenaica de terapias avanzadas en linfoma no Hodgkin (THERAVLINFO)

Vascularized lymphoma on-chip: a multifaceted tool for translational research (MyLymphoTool)

Dual CD19-CAR-T approaches to counteract antigen escape and tumor microenvironment immune suppression in FL

Vascular and extracellular matrix remodeling in follicular lymphoma: implications in the transformation to an aggressive lymphoma and immunotherapy efficacy (VASCEM_LYMPHO)

Patient Derived Organoids 2.0: Annotated immunocompetent organoid platforms in solid and hematological tumors as living labs for the optimization and design of current and novel immunotherapies and cellular therapies. CIBERONC (Strategic Action-Towards Ca

Subscribe to the Newsletter of Clínic